Compare NextEra Energy, Inc. (NEE) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs Sanofi SA — how do they compare? NextEra Energy, Inc. trades at $85.89 (market cap $178.85B), while Sanofi SA trades at $43.66 (market cap $104.30B). The key difference: NextEra Energy, Inc. is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| NEE | SNY | |
|---|---|---|
Market Cap | $178.85B | $104.30B |
Sector | Utilities | Health |
52-Week High | $97.88 | $52.34 |
52-Week Low | $69.77 | $41.33 |
Enterprise Value | $286.18B | $124.19B |
Dividend Yield | 2.91% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $84.70, showing minimal daily movement. The stock exhibits a bearish technical signal despite recent earnings beats in Q1 and Q2 2026. Financially, the company maintains strong profitability with a 32.4% net income margin and benefits from growing electricity demand driven by AI data center expansion, as highlighted in recent partnerships like the $100 billion Kentucky data center project with Brookfield (The Motley Fool, 2026-07-29).
Outlook remains positive due to robust dividend payments and strategic positioning in AI power infrastructure, though risks include high capital expenditures and rising debt levels. Analyst consensus is bullish with a $100.40 price target, suggesting significant upside potential from current levels.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
